<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>drugmaker &#8211; Canyon Crest Guide Local News</title>
	<atom:link href="https://canyoncrestguide.com/tag/drugmaker/feed/" rel="self" type="application/rss+xml" />
	<link>https://canyoncrestguide.com</link>
	<description>Canyon Crest News</description>
	<lastBuildDate>Fri, 31 Oct 2025 22:53:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://canyoncrestguide.com/wp-content/uploads/2023/08/Canyon-Crest-Guide-Local-News-100x100-1-65x65.jpeg</url>
	<title>drugmaker &#8211; Canyon Crest Guide Local News</title>
	<link>https://canyoncrestguide.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Pfizer sues to stop rival bid for drugmaker Metsera by Denmark&#8217;s Novo Nordisk</title>
		<link>https://canyoncrestguide.com/pfizer-sues-to-stop-rival-bid-for-drugmaker-metsera-by-denmarks-novo-nordisk/</link>
		
		<dc:creator><![CDATA[Tony Ramos]]></dc:creator>
		<pubDate>Fri, 31 Oct 2025 22:53:51 +0000</pubDate>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[127075693]]></category>
		<category><![CDATA[article]]></category>
		<category><![CDATA[bid]]></category>
		<category><![CDATA[business]]></category>
		<category><![CDATA[Denmarks]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[drugmaker]]></category>
		<category><![CDATA[General news]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Metsera]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[pfizer]]></category>
		<category><![CDATA[rival]]></category>
		<category><![CDATA[stop]]></category>
		<category><![CDATA[sues]]></category>
		<category><![CDATA[U.S. news]]></category>
		<guid isPermaLink="false">https://canyoncrestguide.com/pfizer-sues-to-stop-rival-bid-for-drugmaker-metsera-by-denmarks-novo-nordisk/</guid>

					<description><![CDATA[[ad_1] Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy</title>
		<link>https://canyoncrestguide.com/sarepta-shares-slide-again-as-drugmaker-bows-to-fda-pressure-to-pause-gene-therapy/</link>
		
		<dc:creator><![CDATA[Tony Ramos]]></dc:creator>
		<pubDate>Tue, 29 Jul 2025 23:07:21 +0000</pubDate>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[123958372]]></category>
		<category><![CDATA[article]]></category>
		<category><![CDATA[bows]]></category>
		<category><![CDATA[business]]></category>
		<category><![CDATA[drugmaker]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Gene]]></category>
		<category><![CDATA[gene therapy]]></category>
		<category><![CDATA[Government regulations]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Men&#x27;s health]]></category>
		<category><![CDATA[pause]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Sarepta]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[slide]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Tuberculosis]]></category>
		<guid isPermaLink="false">https://canyoncrestguide.com/sarepta-shares-slide-again-as-drugmaker-bows-to-fda-pressure-to-pause-gene-therapy/</guid>

					<description><![CDATA[[ad_1] WASHINGTON &#8212; Shares of drugmaker Sarepta Therapeutics continued to sink Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following several patient deaths. The decision, announced late Monday, comes just days after the company rebuffed FDA regulators in an extremely unusual [&#8230;]]]></description>
		
		
		
			</item>
	</channel>
</rss>
